First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari et al. · The Lancet · 2017
Cited by 1,153 works. doi:10.1016/s0140-6736(17)30123-x
Authors
- Jean‐Charles Soria
- Daniel S.W. Tan
- Rita Chiari
- Yi-Long Lung Cancer Wu
- Luis G Paz-Ares
- Juergen Wolf
- Sarayut Lucien Geater
- С. В. Орлов
- Diego Luigi Cortinovis
- Chong‐Jen Yu
- Maximillian Hochmair
- Alexis Benjamin Cortot
- Chun‐Ming Tsai
- Denis Moro‐Sibilot
- Rosario García Campelo
- Tracey McCulloch
- Paramita Sen
- Margaret Han Dugan
- Serafino Pantano
- Fabrice Branle
References
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
- Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
- PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer